ADVERTISEMENT
Videos
Identifying Biomarkers to Predict Resistance to Lutetium-177–PSMA-617
Featuring Oliver Sartor, MD
10/11/2023
At the 2023 EANM meeting, Oliver Sartor, MD, Mayo Clinic, Rochester, Minnesota, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
Transcript:
Transcript to come.
Source:
Sartor O. Prediction of resistance to PSMA-617 Lu-177 by assessment of circulating tumor DNA biomarkers. Presented at the 2023 European Association of Nuclear Medicine Congress; September 9-13, 2023; Vienna, Austria. OP-336.
© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement